Clinical Trials Browser

Phase 2 × pixantrone × 30 days × Clear all

NCT03458260 2026-03-10

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Phase 2 Completed

Recurrence, Lymphoma, Large B-Cell, Diffuse